Synopsis
Quick and comprehensive information on psychotropic drugs for adults.
• Accurate and up-to-date
• Comparison charts help decision-making
• Icons and full color
• Available both in print and online
• Downloadable patient information sheets More about this book: The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.
• Independent, unbiased, up-to-date
• Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options
• Succinct, bulleted information on all classes of medication: on- and off-label indications, (US FDA, Health Canada), recommended dosages, US and Canadian trade names, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more – all you need to know for each class of drug
• Potential interactions and side effects summarized in comparison charts
• With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs. Clearly written patient information sheets can be downloaded as printable PDF files from the Hogrefe website after registration New in this edition:
• Antidepressants chapter revised extensively and includes new sections on the selective serotonin-5-HT1A agonist gepirone and difficult-to-treat depression
• Antipsychotics chapter includes a new section on the muscarinic agonist/antagonist combination (Xanomeline/trospium chloride), a novel treatment that does not block D2 dopamine receptors. Major revisions to TGA Dosing and Pharmacokinetics
• Drugs for Treatment of Dementia chapter includes donanemab infusion
• Drugs for ADHD comparison table expanded
• Drugs of Abuse chapter has been revised extensively and includes a new section on Psychedelics and Dissociative Drugs
• New formulations and trade names include: Abilify Asimtufii (aripiprazole extended-release 2-monthly injection), Azstarys (serdexmethylphenidate/dexmethylphenidate capsules), CAMCEVI (leuprolide 6-month slow-release SC depot injection), Drizalma Sprinkle (duloxetine capsules), Eldepryl (selegiline tablets and capsules), Eprontia (topiramate oral solution), Exxua (gepirone extended-release tablets), Ketalar (ketamine hydrochloride injection), Kisunla (donanemab infusion), Lybalvi (olanzapine/samidorphan tablets), Onyda (clonidine extended-release suspension), Relexii (methylphenidate extended-release tablets), Secuado (asenapine transdermal patch), Zurzuvae (zuranolone capsules)
About the Authors
Ric M. Procyshyn, BScPharm, MSc, PharmD, PhD, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada; British Columbia Mental Health & Substance Use Services Research Institute, Vancouver, BC, Canada.
Katelyn Halpape, BSP, ACPR, PharmD, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.
David D. Kim, BSc, MSc, PhD, Department of Psychiatry and Psychotherapy, Technical University of Munich, Germany.
"About this title" may belong to another edition of this title.
